Entrada Therapeutics, Inc. 8-K Report: Key Shareholder Updates on February 24, 2025

Here is the extracted key information from the provided SEC filing section:

1. Filing Type: The document is an 8-K filing, which is used to report significant events that shareholders should know about.
2. Company Information:

• Name: Entrada Therapeutics, Inc.
• CIK: 0001689375
• SEC Central Index Key (CIK): 0001689375
• IRS Employer Identification Number (EIN): 81-3983399
• Address: One Design Center Place, Suite 17-500, Boston, MA 02210
• Phone Number: (857) 520-9158

3. Stock Information:

• Common Stock Par Value: $0.0001 per share
• Stock Symbol: TRDA
• Exchange: NASDAQ

4. Reporting Period:

• Filing Date: February 24, 2025
• Period Covered: The filing pertains to the date of February 24, 2025.

5. XBRL Information:

• The document is formatted in XBRL (eXtensible Business Reporting Language), which is used for the electronic transmission of business and financial data.

Insights:

• The filing indicates that Entrada Therapeutics, Inc. is actively reporting to the SEC, suggesting it is a publicly traded company with obligations to disclose material information.
• The date of the report (February 24, 2025) suggests that the information is current and may relate to significant business developments or events occurring on that date.
• The presence of the 8-K filing indicates that there may have been a significant event that warranted immediate reporting to shareholders.
• The company is listed on NASDAQ, which may imply a certain level of credibility and adherence to regulatory requirements expected from public companies.

This information is crucial for investors and analysts monitoring the company's activities and financial health.